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Abstract: In the last decade, the advances made into the reprogramming of somatic cells into induced
pluripotent stem cells (iPSCs) led to great improvements towards their use as models of diseases.
In particular, in the field of neurodegenerative diseases, iPSCs technology allowed to culture in vitro all
types of patient-specific neural cells, facilitating not only the investigation of diseases’ etiopathology,
but also the testing of new drugs and cell therapies, leading to the innovative concept of personalized
medicine. Moreover, iPSCs can be differentiated and organized into 3D organoids, providing a tool
which mimics the complexity of the brain’s architecture. Furthermore, recent developments in 3D
bioprinting allowed the study of physiological cell-to-cell interactions, given by a combination of
several biomaterials, scaffolds, and cells. This technology combines bio-plotter and biomaterials in
which several types of cells, such as iPSCs or differentiated neurons, can be encapsulated in order to
develop an innovative cellular model. IPSCs and 3D cell cultures technologies represent the first step
towards the obtainment of a more reliable model, such as organoids, to facilitate neurodegenerative
diseases’ investigation. The combination of iPSCs, 3D organoids and bioprinting will also allow the
development of new therapeutic approaches. Indeed, on the one hand they will lead to the development
of safer and patient-specific drugs testing but, also, they could be developed as cell-therapy for curing
neurodegenerative diseases with a regenerative medicine approach.
Keywords: cell culture; iPSCs; 3D bioprinting; organoids; disease modelling; personalized medicine;
regenerative medicine
1. Introduction
Stem cells represent a very versatile cell source, as they are able to undergo a very high number
of divisions thanks to their self-renewal property and furthermore differentiate into almost all adult
cell types thanks to their pluripotency characteristic [1]. In previous years, the use of stem cells
research was limited, due to invasively harvesting techniques, such as through the bone marrow,
adipose tissue extraction by liposuction or blood apheresis [2]. With the discovery that adult somatic
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cells can be reprogrammed into the so-called induced pluripotent stem cells (iPSCs) this problem
has been mostly overcome, as it is now possible to generate stem cell lines with minimally invasive
techniques, such as skin biopsies or, more recently, blood withdrawals [3]. These recent findings and
the increased availability of iPSCs have led to an outstanding increase in the understanding of disease
mechanisms and in drug screening studies. This is particularly true for neurodegenerative diseases,
as it is impossible to retrieve neural cells from patients. The reprogramming of patient-derived cells
also opens new opportunities for personalized medicine approaches of drug discovery. Moreover,
the development of 3D organoids and the increased relevance of bioprinting techniques provided a
useful tool to generate innovative cell cultures, providing 3D models in which cells can be disposed in
a controlled manner and where they can grow in tissue-like structures [4]. Obviously, 3D bioprinting
opened new possibilities in the field of tissue engineering, but it can be helpful also for disease
modeling. In fact, the generation of a 3D scaffold that can resemble the human tissues will permit
the study of neurodegenerative diseases in the so-called “brain-in-a-dish” approach. Finally, the
combination of 3D bioprinting techniques with iPSCs technology will permit the development of the
most realistic and reliable in vitro cell culture, allowing the study of organoids derived from patients
differentiated cells, leading to a personalized medicine approach in drug testing.
2. Uses of iPSCs in Neurodegenerative Diseases
Recent advances in the field of stem cells research have led to the development of iPSCs, which
result particularly useful when related to neurodegenerative diseases. In particular, the establishment
of human iPS cells has led to have an unlimited source of stem cells overcoming the ethical limits of
human embryonic stem cells, which are obtained from the blastocyst, interrupting the development
of a fertilized embryo [5]. Furthermore, iPSCs can be reprogrammed from any somatic cell line,
allowing a less invasive retrieval and providing a new way to study diseases’ mechanisms which
are patient-specific, opening to the so-called personalized medicine (Figure 1). To further advance
towards this direction, it will become increasingly necessary to fully understand the pathogenic
mechanisms underlying neurodegenerative diseases. Human iPSCs provide a unique opportunity to
fill in some knowledge gaps, such as the genotype-phenotype association of certain neurodegenerative
diseases [6]. Indeed, one of the main advantages of iPSCs is based on the ability of iPSCs to preserve
many features of individual patients [7]. Moreover, neurodegenerative patients can be divided into
several phenotypic categories, thus understanding disparities between such groups may lead to the
finding of better diagnostic markers and to the development of fine-tuned, personalized therapies [8].
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Figure 1. iPSCs obtainment and potential applications. Somatic cells can be taken from several
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for disease modelling, drug discovery, and for cell replacement therapy.
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In recent years, many iPSCs’ lines have been generated from patients with neurodegenerative
diseases, such as Alzheimer’s disease (AD) [9], Parkinson’s disease (PD) [10], Amyotrophic Lateral
Sclerosis (ALS) [11], and Huntington’s disease (HD) [12].
2.1. IPSCs in Alzheimer’s Disease
AD is the most common form of dementia and is characterized by progressive memory-loss and
declining of cognitive functions, which eventually lead to the patient’s death [13]. IPSCs-derived cells
are widely used in AD’s research, and their use as in vitro models allows studies concerning both
the pathogenesis of the disease and its therapy. In particular, they seem to be an appropriate model
for mimicking disease mechanisms, as a higher susceptibility to amyloid beta oligomers (Aβ1-42
oligomers), typical of AD pathology [14], was found in neuronal precursors derived from iPSC of
patients with a mutation in the PSEN1 gene (PSEN1-A246E mutation) [15], and in iPSCs-derived
neurons of sporadic AD patients and of a patient carrying the pathogenic APP-E693∆ mutation [16].
The induction of familiar AD (fAD) mutations in neurons derived from healthy controls could also lead
to in vitro models of the disease, as the expression of the PSEN1∆E9 mutation by genome editing lead
to a decrease in endocytosis and soma-to-axon transcytosis of LDL [17]. Genome editing technology
could also be used for mutations’ correction, generating an isogenic control line [18]. Interestingly,
iPSCs derived from iPSCs of patients with Down Syndrome, which usually have a high risk of early
AD development, allowed the understanding of AD-like initial cellular hallmarks [19]. IPSCs also
assume an important role when it comes to drug screening models. For example, a study found a
reduction of Tau protein after treatment of iPSCs with an inhibitor of γ-secretase [20]. IPSCs-derived
neurons used for drug screening need to be well differentiated, as it was seen that cells have different
susceptibilities to drugs between early and late differentiation stages [21]. Finally, non-neural cells
derived from iPSCs could also prove very useful in disease modeling and drug screening. Many
pathological hallmarks were found aberrant in astrocytes derived from iPSCs of fAD and sporadic
AD patients suggesting that astrocytic atrophy could be a plausible mechanism for early cognitive
impairment [22,23].
2.2. IPSCs in Parkinson’s Disease
PD is the second most common neurodegenerative disease after AD, with a prevalence of 1% in
individuals over age 60 and 4% in individuals over age 85 [24]. Usually iPSCs are differentiated
into dopaminergic (DA) neurons to model PD because the disease is characterized by the loss
of DA neurons of the Substantia Nigra in the midbrain. Since monogenic mutations cause an
idiopathic-like disease, diverse iPSCs lines of patients with Parkin and PINK1 mutations (e.g.,
2–4 exon deletion of Parkin and PINK1 Q456X) have been developed. It was seen that these cells lines
present abnormalities in mitochondrial and dopamine homoeostasis, elevated α-synuclein, synaptic
dysfunction, DA accumulation, microtubular stability, and axonal outgrowth, resulting in an optimal
model of the disease [25,26]. Furthermore, iPSCs obtained from patients presenting the SNCA gene
triplication with elevated α-synuclein showed an impairment of differentiation and maturation [27].
An electrophysiological characterization of control dopaminergic neurons derived from iPSCs was
provided by Hartfield and colleagues, who confirmed that these cells have the physiological hallmarks
of dopaminergic neurons previously reported only on rodent slice [28]. IPSCs have also allowed an
innovative co-culture of microglial cells and cortical neurons, highlighting a unique cytokine profile
impossible to obtain without iPSCs [29]. Interestingly, the pathologic phenotype was reversed in
cortical neurons derived from iPSCs of patients mutated in SNCA using a small molecule found by
yeast screening, opening new possibilities in drug screening and testing [30]. IPSCs also appear to be
fundamental for the development of PD therapy, both for drug screening [30] and stem cell therapy [31].
Indeed, Kikuchi et al. achieved the transplantation of human iPS cell-derived dopaminergic neurons
in a primate model of PD treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, with an increase
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in spontaneous movement of the monkeys, demonstrating for the first time that such transplantation
could be clinically applicable for the treatment of PD patients [31].
2.3. iPSCs in Amyotrophic Lateral Sclerosis
ALS is the most prevalent motor neuron disease and is characterized by the progressive loss of
upper and lower motor neurons (MNs), leading to muscle atrophy, paralysis, and death 2–5 years
after the first diagnosis [11]. MNs derived from iPSCs are the most common neural cell type used
in ALS, useful for understanding disease mechanisms. An increase in oxidative stress and in DNA
damage was found in iPSC-derived C9ORF72 MNs, confirming that the reduction of oxidative stress
could help to delay patients’ death [32]. Moreover, MNs derived from iPSCs with induced mutation in
FUS (P525L) were used to investigate the transcriptome and microRNA, which resulted altered with
implications for ALS pathogenesis [33]. The role of astrocytes was also investigated in both sporadic
and mutant patients, suggesting that in ALS patients the co-culture between MNs and astrocytes
causes alterations in both cell types [34,35]. Genetic engineering allowed the study of ALS-pathways,
as it was found that the activation of AP1 drives neurodegeneration in genetically-corrected SOD1
mutant MNs [36].
IPSCs MNs also proved to be a useful model for drug screening. Small molecule compounds
that regulate IGF-II expression were found to increase MN resilience [37]. Furthermore, Egawa and
colleagues, which firstly generated and characterized MNs from iPSCs of TDP43 mutated patients,
found some pathological hallmark, such as short neurites and abnormal insoluble TDP43. They
then tested trichostatin A, spliceostatin A, garcinol, and anacardic acid and found that the last one,
an inhibitor of histone deacetylase, rescued the pathogenic abnormalities [38].
2.4. iPSCs in Huntington’s Disease
HD is characterized by loss of neurons mainly in the caudate nucleus, putamen, and the cerebral
cortex with affection in a later stage of other areas, e.g., hippocampus and hypothalamus [39]. Even
though the genetic cause for this disease is known, an expansion mutation of the trinucleotide
(CAG) repeat in the HTT (IT15) gene [40], the mechanisms through which mutant HTT results in the
degeneration of selective neurons population are still unclear. Thus, studies on HD models are needed
in order to discover treatments.
Neurons differentiated from iPSCs of patients helped to understand the role of mutant HTT gene
and the mechanisms that lead to the pathology. For example, early molecular changes in intracellular
signaling, expression of oxidative stress proteins, and the p53 pathway were reported in both iPSCs and
in iPSCs-derived neurons [41]. Another study reported changes in neuronal development and adult
neurogenesis, exploiting the iPSCs capacity to model embryonal development [42]. The possibility
to differentiate iPSCs into neurons opened the possibility to discover new therapeutic targets, such
as pre-mRNA trans-splicing modules [43]. Finally, the role of glial cells was investigated in several
studies, such as the one carried out by Hsiao and colleagues, which reported that HD astrocytes
provide less pericyte coverage, reducing their number and promoting angiogenesis [44].
3. From iPSCs to “Brain on a Dish”: Role of Brain Organoids in Neurodegenerative Diseases
In the last few years, advances have been made to move on from a 2D to a 3D approach in order
to gain further insights into the cytoarchitecture of the brain and into the disease mechanisms that may
take place in the central nervous system. Both methods present with advantages and disadvantages:
while 2D models with directed monolayer differentiation may provide an easier substrate for imaging
assays and morphological studies such as dendrite complexity, 3D cultures can result in a large
diversity of cell types and allow the study of cell-cell interactions between different populations [45,46].
3D human brain cultures are usually obtained with the differentiation of iPSCs into either neural cell
aggregates or into more complex brain organoids. Neural cell aggregates are usually generated from
human neural progenitors cultured in a 3D suspension, whilst brain organoids are mainly derived
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with serum-free floating culture of embryoid body-like aggregates [47] (Figure 2). Lancaster et al. used
a derivation of this last method to obtain a novel class of organoids known as “mini-brains”, containing
various discrete but interdependent brain regions [48]. Brain organoids actually have certain limits,
because not every aspect of brain diseases can be represented by such models, but future studies will
allow to advance brain organoid techniques for modeling neurodegenerative diseases, thus elucidating
novel aspects of disease pathogenesis [49].
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3.1. Applications of Brain Organoids
Even more than with iPSCs, brain organoids will help us gain insights into disease mechanisms
of neuronal disorders and indeed will provide a useful tool for drug screening and new therapeutic
approaches. The first and main application for these 3D cultures is the study of neurodevelopmental
disorders, which has found great interest and made major advances with the rise of these cultures.
Brain organoids derived from iPSCs of patients were fundamental in identifying developmental
abnormalities and even new target genes in complex neurodevelopmental diseases, such as autism
spectrum disorders [50] and microcephaly [48]. Furthermore, they resulted useful even in modeling
the effects of viruses such as the Zika virus on brain development, providing a useful tool for
drug screening and potential therapeutic strategies [51]. More recently, combined approaches of
3D modeling and genetically engineering allowed the development of cerebral organoids to model
brain tumors, providing a platform for investigating the tumor biology of such aggressive cancers and
new preclinical model for drug screening [52]. Lastly, nowadays brain organoids are gaining a more
prominent role also for the study of neurodegenerative diseases (Figure 3).
Brain Organoids in Neurodegenerative Diseases
When considering brain organoids and neurodegenerative diseases, it must be taken into
consideration the late-onset of these diseases, which usually occur when the brain is fully formed,
resulting in a need to create a more “aged brain”. Although not every aspect of the aged brain can be
modeled by such organoids, earlier events in disease progression may share molecular and cellular
mechanisms that usually appear at later stages in neurodegenerative diseases [49]. Indeed, cerebral
organoids have still proven to be a useful tool for the study and drug screening of neurodegenerative
diseases such as AD, HD, and PD [47,53]. Raja et al. obtained a self-organizing 3D human formation
from iPSCs derived from AD patients with a duplication in the APP gene. These structures presented
with the main hallmarks of the disease, Aβ aggregation and Tau phosphorylation, and they proved
useful for the screening of b- and y-secretase inhibitors, which resulted in a decrease of the aggregates
formation [54]. For Huntington’s disease, 3D organoids allowed the study of the effect of the huntingtin
mutation on aspects of neuronal development such as abnormal cell organization and precocious
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acquisition of mature neuronal identities. Indeed, also in this case, pharmacological intervention
rescued the correct neuronal differentiation [55]. Regarding Parkinson’s Disease, only one organoid
model has been developed, containing the G2019S LRRK2 mutation, which highlighted the synaptic
dysfunction pathway as the most altered one in patients derived organoids. Intriguingly, this work
also derived gastrointestinal organoids from the iPSCs of the same class of patients, highlighting
differences in gene expression of intestinal cells of patients as opposed to controls [56].Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  6 of 13 
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3.2. Future Advances for 3D Cultures: Importance of Biomaterials
There are some limitations with 3D brain organoids, the main one being the limited reproducibility
of these cultures. This is particularly true for 3D organoids which aim to mimic later stages of
development, as the proportion of cell types which can generate from iPSCs may diverge resulting
in non-identical models [45]. To overcome this, fundamental will be the use of biomaterials, which
will allow the scaffolding of brain cultures, creating a niche-like effect and confining progenitors
in a non-uniform environment which can resemble the actual situation present in during neural
development. Substrates like the hydrogel are first of all highly programmable and can, furthermore,
be manipulated both in their pore size and physical properties, creating more complex structures
which can “aid” the neural differentiation of progenitors [57].
4. Recent Developments in 3D Bioprinting
3D bioprinting is an emerging technology, used for the manufacture and the generation of
artificial tissues and organs [58], adding new approaches to tissue engineering (TE) and regenerative
medicine, such as the manufacture of scaffolds to support cells, as well as in situ deposition of cell
suspensions [59]. Bioprinting technology has allowed to overcome several limits, such as the control of
Int. J. Mol. Sci. 2018, 19, 3972 7 of 13
in vitro 3D biological structures and cellular distribution [60]. Bioprinting, through the use of hardware
and software, has been used in particular for the design of three-dimensional structures, allowing the
creation of “organoids” for biological and pharmacological studies, and the repair and replacement of
human tissues (Figure 4).
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Figure 4. 3D bioprinting technology. Hydrogel and iPSCs are combined to obtain a bioink, which can
then be used to design and print three-dimensional structures, such as organoids.
One of the fundamental elements that characterizes the bioprinting process is the development of
biomaterials, which must have specific characteristics: biocompatibility, printability, and the ability
to maintain a three-dimensional structure once printed and kept in culture [58]. The main feature of
the hydrogel, the main biocompatible material used as a three-dimensional support for cell growth, is
the ability to be extremely hydrophilic, making it an excellent candidate in terms of biocompatibility
for its use in bioprinting. It was initially used in TE because it was able to simulate the extracellular
matrix, guaranteeing cell growth and communication [61]. Several cell types associated with different
biomaterials that compose the bioink have already been used in several research areas, where cellular
viability and motility have been demonstrated, as well as a spatial organization similar to in vivo
tissue [62]. Researchers tend to create a combination of biomaterials for each cell type, and with
well-defined printability specifications, so as to make the process as standardized and reproducible as
possible, despite being a very open field and full of new developments. New generation bioinks
are now able to maintain each of these characteristics, thus improving the success in terms of
bioprinting [63].
3D Bioprinting and Neurodegeneration
In the last decade, the possibility of replacing dead cells in neurodegenerative processes paved the
way for a more intense and accurate study of stem cells and their potential ability to replace damaged
tissue [64]. It was also thought to exploit the ability of stem cells to secrete cytokines and growth
factors, offering benefits such as anti-inflammatory effects, protection of neural cells, and endogenous
recovery systems. Transplanting these cells into da aged sites presents various problems such as
low cell survival and limited engraftment [65]. To minimize these problems, it was decided to use
three-dimensional scaffold printing that mimic the complexity both from the biological and functional
point of view of the tissue to be replaced [66].
The manufacture of three-dimensional prefabricated scaffolds has already given positive results
in the treatment and repair of spinal and nerve damage, but with a great limitation in terms of
control of the external shape of the scaffold and of its internal architecture [67,68]. These problems
have been overcome with 3D bioprinting, which leaves the operator complete freedom regarding
the shape, the material, and its internal architecture. The recent developments in the field of 3D
bioprinting are mostly focused on regenerative medicine, to respond to the growing demand for
tissues and organs for transplants, arriving only later to the application of this technology to basic
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scientific research. Until now only a few studies have focused on using 3D printing applied to
the creation of neural tissue, compared to other widely studied tissues such as skin, bones, heart
tissue, and cartilaginous structures [69]. For neural tissue Lozano and colleagues developed a novel
printing technique for engineering 3D brain structures to model neurodegenerative diseases. They
encapsulated primary cortical neural cells in gellan gum modified with RGD peptides. They found
that cortical neurons remained viable throughout the printed construct and exhibited differentiated
neurons morphology [70]. Moreover, Kuzmenko and colleagues proposed nanofibrillated cellulose
(NFC) functionalized with carbon nanotubes (CNTs) as a supporting material for neural cells. They
hypothesized that NFC provides a surface roughness that enhances attachment of cells, while the
functionalization with CNTs allows significant improvement of cellulose conductivity (about 105 times
increase), favoring communications between cells and generation of a neural network [71]. In our
experience, we tested hydrogels with several concentrations of sodium alginate and gelatin [72].
Specifically, we found that the best bioink for neural cells in terms of proliferation, viability, and
structural support is the one composed of 6% of sodium alginate and 4% gelatin. Our data suggest
that the bioink we developed improves cellular proliferation, compared with 2D standard cell cultures,
obtaining in less time a larger number of cells with an increased viability. The three-dimensionality,
fundamental for cell-to-cell communication, is also maintained. The printing process was standardized
in term of print pressure, temperature, and speed, to print our hydrogel with Cellink INKREDIBLE+
bioplotter, with a good repeatability and a robust preparation protocol. Indeed, it is necessary to
establish a repeatable 3D bioprinting protocol, in order to standardize cellular differentiation and
factors deposition, to facilitate cell organization, and also because matrigel-based cell cultures do
not guarantee a defined 3D spatial assembling. In the future, we will test electrical communication
between neural cells in printed construct, in order to verify the network operation, using differentiated
neural stem cells, and to create a detailed and realistic neural tissue [72].
Recently, researchers also think that the nervous tissue printed in 3D may be used for the neural
regeneration, a with very large potential in the field of neurodegeneration to replace degenerated
neural tissue [73,74]. Obviously, 3D bioprinting is a relatively new application to the tissue engineering
field, opening the possibility to generate a remarkable biomimicry, which could replace the current
gold standard of autografts [75,76]. 3D bioprinting technologies allow several adjustments to the
shape, porosity, and size of the 3D bioprinted scaffolds, which could make them more suitable in
the repair of the lesion site in neurodegenerative diseases with respect to simply delivering the cells
using injectable hydrogels. Even so, but several challenges remain, such as the development of bioinks.
Probably, in the future, it will be necessary to develop new biomaterials and increase the precision of
bioplotter, allowing the generation of accurate 3D structures [77].
The creation of nerve tissue by bioprinting is also used for pharmacological studies, for
toxicological screening, and for basic research. It is necessary to underline how this field is still
in its infancy, how it is necessary to validate this model for the applications described up to now, to be
sure that the model completely recapitulates the pathophysiology that we want to investigate with
this tool [66] in particular with regard to neurodegenerative diseases.
5. Conclusions
In the last decade, two groundbreaking discoveries, i.e., somatic cells reprogramming into iPSCs
and 3D bioprinting, changed the way of modeling diseases, in particular for those pathologies difficult
to study in a simple cell culture, such as neurodegenerative diseases. The first permitted to obtain
neural cell cultures in few months starting from adult somatic cells, like fibroblasts and peripheral
blood mononuclear cells, while 3D bioprinting consists in the print of hydrogel and cells, to generate
models that imitate tissue characteristics. While iPSCs are differentiated into neurons and, furthermore,
into brain organoids in many papers for disease modeling, 3D bioprinting is actually used for few
tissues, like cartilage, bone, and heart. Neural 3D cell cultures are still in development, there are no
target bioinks and the studies that combine neuronal cells and 3D bioprinting is more complicated
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with respect to other tissues because of the fragility of such cells. Despite this hurdle, the possibility to
create an in vitro neural tissue would open many fields of research that are unreachable today; first of
all, the opportunity to study the 3D spatial connection between different neuronal populations, and
how they communicate with each other. In combination with iPSCs and organoids technology, we
can create a physiological model to understand physiological and pathological mechanisms, to better
understand mechanisms underlying neurodegenerative diseases.
Finally, the combination between 3D bioprinting and organoids will open new possibilities
in many fields: drug screening, replacing expensive in vivo experiments, and overcoming animal
models’ issues, but also personalized medicine thanks to the use of cells derived from patients. More
intriguingly, the generation of a 3D neural tissue composed of patient’s cells will allow so-called
neuro-regeneration, opening the possibility to replace a degenerated tissue.
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